AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$2.59 USD
-0.15 (-5.47%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.67 +0.08 (3.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ABCL 2.59 -0.15(-5.47%)
Will ABCL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABCL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABCL
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
GSK (GSK) Tops Q2 Earnings and Revenue Estimates
ABCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for ABCL
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Tracking Baker Brothers Portfolio - Q2 2024 Update
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!